Bladder transitional cell carcinoma

This large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …

This early-phase trial is testing whether adding an experimental drug called emavusertib (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced urothelial cancer whose tumors have become resistant to PD-1/PD-L1 blockers. The study will enroll 27 adults and f…

This early-phase trial tests a combination of three drugs—enfortumab vedotin, pembrolizumab, and quemliclustat—in people with advanced bladder or urinary tract cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and effective. The…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests a decision tool to help select women with bladder cancer who can safely keep their reproductive organs during bladder removal surgery. Currently, standard surgery removes the bladder, uterus, ovaries, and part of the vagina, which can harm sexual health, mental h…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This phase III trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to initial immunotherapy. About …

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants receive the drug alone, while others get it combined with another cancer drug. The goal is to check safety, how well it works, and how it affects the body. Abou…

This phase 2 trial tests whether adding one of four different drugs to a standard immunotherapy combination can help people with HER2-positive muscle-invasive bladder cancer avoid bladder removal. Participants receive disitamab vedotin and toripalimab plus a sensitizing agent, th…

This study looks at whether taking vitamin B3 (a common dietary supplement) can stop antibiotics from weakening the immune system's ability to fight bladder cancer. The trial includes people with a certain type of bladder cancer who have recently taken antibiotics. They will rece…

This Phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) before bladder removal surgery can completely eliminate the cancer in people with a rare, aggressive form of bladder cancer called small cell neuroe…

This study looks at whether surgery to remove remaining cancer spots can help people with advanced bladder cancer that has been controlled by drug therapy. About 32 adults whose cancer has not spread widely will receive surgery on the main tumor and any other treatable spots. The…

This phase II trial is testing the drug pemetrexed in people with advanced bladder cancer or other solid tumors that have spread and carry certain gene mutations (MLL4, UTX, or MTAP). The goal is to see if pemetrexed can shrink tumors. About 64 participants will receive the drug …

This early-stage trial is testing whether it is safe to give immunotherapy (nivolumab) together with radiation therapy after bladder cancer surgery. The study will enroll 10 people who have had their bladder removed. The main goal is to see if this combination causes serious side…

This study tests whether a procedure that filters a patient's blood (therapeutic plasma exchange) can help standard cancer drugs work better in people with advanced bladder or urinary tract cancer that has stopped responding to previous treatments. About 70 adults will be randoml…

This early-phase trial is testing whether combining two drugs—cabozantinib and enfortumab vedotin—can safely treat advanced bladder cancer that has spread. About 32 adults whose cancer worsened after standard treatments will receive the combo. The study aims to find the best dose…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This early-stage study tests a new treatment for people with advanced bladder cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins on cancer cells. Participan…

This phase 3 trial is testing a new version of the BCG vaccine, called Verity-BCG, against the standard BCG treatment (OncoTICE) in 540 people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG before. The goal is to see if Verity-BCG is a…

This study tests whether a maintenance drug (pembrolizumab) can help control advanced bladder cancer after an initial 18-week combination treatment. About 97 people who have not had prior therapy for metastatic disease will participate. The goal is to see if this approach improve…

This study tests whether giving a targeted drug (enfortumab vedotin) plus an immunotherapy (pembrolizumab) before surgery to remove part or all of the bladder can improve outcomes for people with advanced bladder or urinary tract cancer. About 75 adults with cancer that has sprea…

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…

This phase II trial tests two drugs—enfortumab vedotin and pembrolizumab—in 20 people with high-grade upper tract urothelial cancer who cannot or choose not to have surgery to remove the kidney and ureter. The goal is to see if the combination can control the cancer and preserve …

This study tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for adults with advanced solid tumors (like breast, colon, or kidney cancer) that have not responded to standard therapies. The main goal is to check the safety of t…

This study tests two drugs, futibatinib and durvalumab, given before surgery to remove the bladder in people with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this combination can eliminate or shrink the cancer enough to improve outc…

This study tests whether adding focused radiation to standard treatment helps people with metastatic bladder cancer live longer. It includes patients whose cancer has not worsened after initial therapy and who have three or fewer remaining tumors. About 130 participants will be r…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This study is testing whether an ultrasound-guided core needle biopsy can accurately determine the stage of bladder cancer. Researchers will compare the biopsy results with the final stage found during standard surgery. The goal is to see if this less invasive method can be a rel…

This study is testing whether a special MRI scan (mpMRI) can accurately diagnose muscle-invasive bladder cancer without needing an invasive biopsy (TURBT). Researchers will compare the MRI results to the biopsy results in 30 adults with suspected muscle-invasive bladder cancer. I…

This study is developing a new DNA test that looks for key genetic changes in bladder cancer tumors. Researchers will collect tumor samples from 400 patients to build and validate the test. The goal is to create a cost-effective tool that helps doctors predict which patients are …

This study is testing a new urine test called Bladder EpiCheck to see how well it can detect bladder cancer in people aged 45 and older who have blood in their urine. Researchers will compare the test results to standard cystoscopy (a camera exam of the bladder). The goal is to f…

This study is testing whether specially trained dogs can detect bladder cancer by smelling urine samples. Researchers will collect urine from 340 adults scheduled for bladder surgery and see how often the dogs correctly identify cancer. If it works, this could lead to a simple, n…

This study is looking at whether analyzing DNA and proteins in urine can help detect cancers of the bladder and kidney without invasive procedures. Researchers will collect urine samples from 500 adults, including those with known or suspected cancer and healthy volunteers. The g…

This study tests whether adding acupuncture to virtual exercise can help manage nerve pain caused by a specific bladder cancer treatment (EV-Pembro). About 50 adults with advanced bladder cancer will be split into two groups: one gets acupuncture plus virtual exercise, the other …

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study looks at whether walking 8,000 to 10,000 steps each day for four weeks before bladder cancer removal surgery can lower the chance of problems after the operation. About 146 adults with bladder cancer who are scheduled for surgery will take part. Half will be asked to i…

This study looks at whether placing a small tube (stent) in the urinary tract after bladder removal surgery affects recovery. About 70 adults with bladder or pelvic cancers will be randomly assigned to get a stent or not. The main goal is to see if avoiding stents lowers the risk…

This study is observing how bladder cancer is treated in Russia and how common certain markers (HER2 and PD-L1) are in different stages. Researchers will look at medical records of 600 people with bladder cancer to see what treatments they receive and how the disease progresses. …

This study collects tissue and blood samples from 1,500 people with prostate or bladder cancer that has come back or spread. Researchers will analyze the samples to find genetic changes and other markers that may explain why some cancers stop responding to treatment. The goal is …

This study is for 150 adults having surgery for bladder cancer. Researchers want to see if the amount of fluid absorbed during surgery and changes in DNA in the blood can help predict if the cancer will return or get worse. The goal is to improve how doctors assess risk and plan …

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…